StockData

Lipocine vs Xenon Pharmaceuticals

LPCN and XENE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LPCN and XENE compare

Xenon Pharmaceuticals is the larger company, worth 278 times as much as Lipocine ($3.8B against $13.7M).

Lipocine grew revenue faster over the last twelve months (−62.7% versus −100% for Xenon Pharmaceuticals).

Lipocine scores higher on the StockData Score (9 against 7 for Xenon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLPCNXENE
Size and price
Market cap$13.7M$3.8B
Share price$1.66$39.26
Change, 1 year−41.1%−1.9%
Change, 5 years−91.4%43.1%
Beta (5Y)−0.430.24
Employees14370
StockData Score
Total score9 (better)7
Valuation score3 (better)0
Growth score1 (better)0
Performance score01 (better)
Health score56 (better)
Dividend score00
Valuation
P/S8.7×–
P/B0.6× (better)3.1×
FCF yield–−8.9%
Fair value$2.62–
Margin of safety36.5%–
Growth
Revenue growth (TTM)−62.7% (better)−100%
Revenue growth, 5Y average–−25.3%
Profitability
Operating margin−801%–
Net margin−755%–
Return on equity−60.9%−43.6% (better)
Return on invested capital–−152%
Financial health
Debt / equity0.000.00
Current ratio11.4821.02 (better)
Altman Z-score−9.2840.87 (better)
Piotroski F-score13 (better)
Dividends and buybacks
Buyback yield−119%–
Shareholder yield−119%0.00% (better)
Ownership
Held by institutions36.2%104%
Held by insiders9.0%0.17%
Insider net buying, 12 months$596K (better)−$20.3M
Superinvestors holding–1
Short interest, % of float4.3%7.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.